Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. (Q54945635)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. |
scientific article |
Statements
1 reference
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. (English)
1 reference
1 reference
P A Ascierto
1 reference
R Gutzmer
1 reference
A Testori
1 reference
L Demidov
1 reference
R Ridolfi
1 reference
D Schadendorf
1 reference
P Queirolo
1 reference
A Santoro
1 reference
C Loquai
1 reference
B Dreno
1 reference
A Hauschild
1 reference
E Schultz
1 reference
T P Lesimple
1 reference
N Vanhoutte
1 reference
B Salaun
1 reference
S Jarnjak
1 reference
P M De Sousa Alves
1 reference
J Louahed
1 reference
V G Brichard
1 reference
F F Lehmann
1 reference
8 August 2016
1 reference
1 reference
1
1 reference
4
1 reference
e000068
1 reference
Identifiers
1 reference
1 reference